SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021.

Ireland, G; Whitaker, H; Ladhani, SN; Baawuah, F; Subbarao, S; Linley, E; Warrener, L; O'Brien, M; Whillock, C; Martin, O; et al. Ireland, G; Whitaker, H; Ladhani, SN; Baawuah, F; Subbarao, S; Linley, E; Warrener, L; O'Brien, M; Whillock, C; Martin, O; Moss, P; Ramsay, ME; Amirthalingam, G; Brown, KE (2022) Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Euro Surveill, 27 (1). ISSN 1560-7917 https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114
SGUL Authors: Ladhani, Shamez Nizarali

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (207kB) | Preview

Abstract

Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2-4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2-4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.

Item Type: Article
Additional Information: This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
Keywords: Antibody, AstraZeneca, Comirnaty, Vaxzevria, COVID-19, COVID-Vaccine, Immunity, Pfizer, Spike Protein, COVID-19, COVID-19 Vaccines, Humans, London, SARS-CoV-2, United Kingdom, Humans, London, United Kingdom, COVID-19, SARS-CoV-2, COVID-19 Vaccines
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Euro Surveill
ISSN: 1560-7917
Language: eng
Dates:
DateEvent
6 January 2022Published
21 December 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDUK Health Security AgencyUNSPECIFIED
PubMed ID: 34991777
Web of Science ID: WOS:000747830100006
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114115
Publisher's version: https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114

Actions (login required)

Edit Item Edit Item